NFKB2 and B-cell chronic lymphocytic leukemia: Importantly, a comprehensive study using whole genome sequencing confirmed that BIRC3 and TRAF3 are recurrently mutated in CLL, and that NFKB2 was a novel prognostic driver which conferred shorter time to treatment [14].